Persistence is the key to success. After 20 years of hard work, CHARSIRE has developed the world’s leading patented technology platform of “Multiple Carbohydrate Complex MGC”. It has the characteristics of short research and development time and low costs, which greatly shortens the time for new drug development and will make great contributions in the medical field.
Charsire innovates the development of new topical medication and and masters a numbers of R&D achievements. Charsire obtained invention patents in 16 countries including the United States, the European Union, and China. Various research breakthroughs and major discoveries are made.
The Phase II trial of the US FDA for new dementia drug BAC has completed.
Charsire’s new drug for Alzheimer’s disease and vascular dementia has completed the Phase II clinical trial approved by the US FDA and successfully found the drug response group.
The new drug for diabetic ulcer wounds has completed the Phase II clinical trial approved by the US FDA and obtained the approval of Taiwan’s Class II medical device.
Charsire’s new radiodermatitis drug ACA has completed the Phase I clinical trial, which can effectively reduce side effects such as pain and skin reaction during radiotherapy, and improve quality of life and effect of radiotherapy patients.
| Year | Patent Description |
|---|---|
| 2022 | The United States- utility patent for the application in breast cancer |
| 2021 | The United States- utility patent for relief of cancer pain and/or skin inflammation caused by radiotherapy |
| 2021 | Canada- utility patent for the synergistic effect of chemotherapeutic drugs for brain diseases and breast cancer |
| 2021 | Republic of China (Taiwan)- utility patent for relief of cancer pain and/or skin inflammation caused by radiotherapy |
| 2020 | Singapore- utility patent for the synergistic effect of diabetic ulcer wounds, brain disease, and breast cancer chemotherapy drugs |
| 2020 | The United States- utility patent for brain disease |
| 2018 | Japan- utility patent for the synergistic effect of diabetic ulcer wounds, brain disease, and breast cancer chemotherapy drugs |
| 2018 | Republic of China (Taiwan)- utility patent for the synergistic effect of diabetic ulcer wounds, brain disease, and breast cancer chemotherapy drugs |
| 2018 | Korea- utility patent for the synergistic effect of chemotherapeutic drugs to reduce the side effects of chemotherapy |
| 2018 | Russia- utility patent for brain disease |
| 2018 | Australia, invention patents for diabetic ulcer wounds, brain disease, breast cancer and the addition of chemotherapy drugs. |
| 2017 | India, Invention Patents for Skin Medicine. |
| 2013 | Korea, invention patent of skin medicine. |
| 2013 | Korea, invention patent of skin medicine. |
| 2013 | Malaysia, Skin Medicine Invention Patent. |
| 2013 | Korea, invention patent of skin medicine. |
| 2012 | Canada, Skin Medicine Invention Patent. |
| 2011 | Japan, Invention Patent for Skin Medicine. |
| 2011 | Republic of China, invention patent of skin medicine. |
| 2010 | Australia, Skin Medicine Invention Patent. |
| 2008 | Singapore, the invention patent of skin medicine. |
| 2008 | Mainland China, invention patent of skin medicine. |
| 2007 | European Union, skin medicine invention patent. |
| 2007 | U.S., skin medicine invention patent. |
| 2006 | In the United States, the first medical invention patent was officially obtained. |